Donepezil

From Proteopedia

proteopedia linkproteopedia link

Revision as of 09:53, 30 November 2010 (edit) David Canner (Talk | contribs) ← Previous diff		Revision as of 09:54, 30 November 2010 (edit) (undo) David Canner (Talk | contribs) Next diff →
Line 16:		Line 16:
	|-		|-
	! Parameter		! Parameter
-	! Aricept	+	! [[Donepezil]]
-	!	+	! [[Tacrine]]
-	!	+	! [[Rivastigmine]]
-	!	+	! [[Galantamine]]
	|-		|-
	! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)		! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)

---

Revision as of 09:54, 30 November 2010

spinqualitylabelsall models Donepezil, also known as Aricept Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

Better Known as: Aricept

• Marketed By: Eisai & Pfizer
  
• Major Indication: Alzheimer's Disease
  
• Drug Class: Acetylcholinesterase Inhibitor
• Date of FDA Approval (Withdrawn): 1996 (2008)
  
• 2006 Sales: $800 Million
• Why You Should Care: One of the most effective treatments for teh symptoms of Alzheimer's Disease, although no definitive proof exists as to whether to alters the progression of the disease.
• The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

Mechanism of Action

Pharmacokinetics

Aceylcholinesterase Inhibitor Pharmacokinetics
Parameter	Donepezil	Tacrine	Rivastigmine	Galantamine
Tmax (hr)
Cmax (ng/ml)
Bioavailability (%)
Protein Binding (%)
T1/2 (hr)
AUC (ng/ml/hr)
IC50 (nM)
Equivalent LDL Reduction Dosage (mg)
Metabolism

References